Do MicroRNAs Cause Mayhem Across Frontotemporal Dementia Spectrum?
Whether by themselves or in the company of mutations that cause frontotemporal dementia, microRNAs may play a hand in driving disease.
1380 RESULTS
Sort By:
Whether by themselves or in the company of mutations that cause frontotemporal dementia, microRNAs may play a hand in driving disease.
At Duke University, researchers discussed how injected stem cells might be tracked and used to treat neurodegenerative diseases.
Basic preclinical discoveries keep meeting vibrant for neurodegenerative disease researchers from around the world
A micro-immunoelectrode allows researchers measure Aβ levels in the interstitial fluid of mice every 30 seconds.
Protein touted as a peripheral monocyte receptor that worsens amyloid plaque pathology in transgenic mice.
After lighting up microglia in mouse models of AD, a tracer is headed for clinical trials.
A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
Tiny secreted vesicles emerge as important players in communication between brain cells. Are they important in neurodegeneration?
A new trend in cell biology points to vesicles released from cells as agents that form and spread pathogenic proteins.
Lipoprotein cap on pigment cell exosomes is essential for production of an amyloid scaffold that concentrates melanin.
At CTAD, former FDA neurology leader Rusty Katz urged Alzheimer’s trialists to stop fussing over disease progression. He recommended going after a large effect, regardless of whether it can garner a label of disease modification. That, he says, may mean combination trials.
A CAP symposium opened the CTAD conference, indicating that presymptomatic treatment and “federated” research have become mainstream thinking in Alzheimer’s therapy development. EPAD is pulling together European sites.
Researchers at CTAD reported seeing biomarkers budge in active and passive immunotherapy trials, but measurement techniques and screening protocols still need improvement for early stage trials to succeed.
Researchers at CTAD announced the end for two active immunotherapies, along with the curious story of a placebo as a treatment and the start of a new antibody.
Using creative ways of mining genetic data, researchers are coming up with new risk variants for Alzheimer’s.